scholarly journals Elevated mean platelet volume is a marker of acute coronary syndrome

2014 ◽  
Vol 42 (2) ◽  
pp. 45-50 ◽  
Author(s):  
S Pervin ◽  
S Ferdoushi ◽  
M Hossain ◽  
AI Joarder ◽  
T Sultana
Keyword(s):  
Acute Coronary Syndrome ◽  
Early Detection ◽  
Troponin I ◽  
Thrombus Formation ◽  
Clinical Pathology ◽  
Signs And Symptoms ◽  
Clinical History ◽  
Cardiac Biomarkers ◽  
Coronary Syndrome ◽  
Anti Platelet Therapy

Acute coronary syndrome (ACS) is a set of signs and symptoms due to rupture of a plaque and are a consequence of platelet rich coronary thrombus formation. Platelet parameters especially MPV could be an important and reliable markers in early detection of ACS when other markers are not available. This quasi- experimental study was conducted from September 2011 to August 2012 in the Department of Clinical Pathology, BSMMU, in collaboration with Department of Cardiology, BSMMU and BIRDEM on 79 patients with ACS diagnosed on the basis of clinical history, Electrocardiographic changes and increased cardiac markers especially troponin I with 63 subjects enrolled as control. For determination of platelet parameters, the blood sample was obtained from all patients of ACS before anti-platelet therapy when patient attended in the Cardiac emergency department and on 5th day of ongoing anti-platelet therapy in coronary care unit. The sensitivity, specificity, accuracy, positive and negative predictive value of platelet counts and MPV were 83%, 28.1%, 42.3%, 37.6%, 64% and 90.6%, 49.4%, 64.8%, 51.6%, 89.8% respectively. In our study, we found that MPV had higher sensitivity and specificity in contrast to platelet count. MPV may used as predictor for early detection of ACS and risk stratification when other cardiac biomarkers are negative. DOI: http://dx.doi.org/10.3329/bmj.v42i2.18985 Bangladesh Med J. 2013 May; 42 (2): 45-50

Assessing the Performance of a Novel Point-of-Care Qualitative Assay for Early Diagnosis of Acute Coronary Syndrome

Cardiology ◽  
2020 ◽  
pp. 1-8
Author(s):  
Ronny Alcalai ◽  
Boris Varshisky ◽  
Ahmad Marhig ◽  
David Leibowitz ◽  
Larissa Kogan-Boguslavsky ◽  
...  
Keyword(s):  
Acute Coronary Syndrome ◽  
Chest Pain ◽  
Diagnostic Accuracy ◽  
Diagnostic Performance ◽  
Troponin I ◽  
Point Of Care ◽  
Final Diagnosis ◽  
Cardiac Biomarkers ◽  
Fatty Acid Binding ◽  
Coronary Syndrome

<b><i>Background:</i></b> Early and accurate diagnosis of acute coronary syndrome (ACS) is essential for initiating lifesaving interventions. In this article, the diagnostic performance of a novel point-of-care rapid assay (SensAheart<sup>©</sup>) is analyzed. This assay qualitatively determines the presence of 2 cardiac biomarkers troponin I and heart-type fatty acid-binding protein that are present soon after onset of myocardial injury. <b><i>Methods:</i></b> We conducted a prospective observational study of consecutive patients who presented to the emergency department with typical chest pain. Simultaneous high-sensitive cardiac troponin T (hs-cTnT) and SensAheart testing was performed upon hospital admission. Diagnostic accuracy was computed using SensAheart or hs-cTnT levels versus the final diagnosis defined as positive/negative. <b><i>Results:</i></b> Of 225 patients analyzed, a final diagnosis of ACS was established in 138 patients, 87 individuals diagnosed with nonischemic chest pain. In the overall population, as compared to hs-cTnT, the sensitivity of the initial SensAheart assay was significantly higher (80.4 vs. 63.8%, <i>p</i> = 0.002) whereas specificity was lower (78.6 vs. 95.4%, <i>p</i> = 0.036). The overall diagnostic accuracy of SensAheart assay was similar to the hs-cTnT (82.7% compared to 76.0%, <i>p</i> = 0.08). <b><i>Conclusions:</i></b> Upon first medical contact, the novel point-of-care rapid SensAheart assay shows a diagnostic performance similar to hs-cTnT. The combination of 2 cardiac biomarkers in the same kit allows for very early detection of myocardial damage. The SensAheart assay is a reliable and practical tool for ruling-in the diagnosis of ACS.

scholarly journals miRNA miRNA on the Wall, Who Is the Most Cardio-Specific of Them All? Circulating microRNAs as Potential Biomarkers in Acute Coronary Syndrome

2021 ◽  
Author(s):  
Prima Hapsari Wulandari
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Troponin T ◽  
Kidney Diseases ◽  
Cardiac Ischemia ◽  
Cardiac Biomarkers ◽  
Coronary Syndrome ◽  
Artery Disease ◽  
Prompt Diagnosis

Abstract The severe and acute manifestation of coronary artery disease (CAD) is acute coronary syndrome (ACS); therefore, prompt diagnosis can save lives. Cardiac biomarkers that are accepted to use in evaluating ACS are creatine kinase muscle/brain subtype (CK-MB), cardiac troponin I (CTnI), or cardiac troponin T (CTnT). However, these markers have several drawbacks, such as prolonged time to rise for prompt diagnosis and elevation in patients with chronic kidney diseases (CKD). Lately, potential, novel candidates for cardiac ischemia biomarkers have been developed, one of which is micro-ribonucleic acids (miRNAs). miRNAs are potential due to their remarkable reproducibility and stability. Several miRNAs, such as, miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and miR-499a, greatly rise in concentration in the plasma or serum of patients with acute cardiac ischemia, signifying their cardiac specificity and promising biomarkers in patients with ACS. This systematic review aims to elucidate the role of cardio-specific miRNA in acute myocardial ischemia (AMI) and its relationship with other cardiac biomarkers.

Women and men diagnosed with acute coronary syndrome – sex-related differences

2018 ◽  
Vol 87 (2) ◽  
pp. 92-98
Author(s):  
Magdalena Dudek ◽  
Marta Kałużna-Oleksy ◽  
Jacek Migaj ◽  
Ewa Straburzyńska-Migaj
Keyword(s):  
Acute Coronary Syndrome ◽  
Troponin I ◽  
Sudden Cardiac Arrest ◽  
Coronary Intervention ◽  
Cardiac Biomarkers ◽  
Invasive Treatment ◽  
Coronary Syndrome ◽  
Significant Difference ◽  
Choice Of Treatment ◽  
Artery Disease

Background. Coronary artery disease (CAD) is one of the most important causes of death in both men and women. There are many gender differences among patients with CAD, including risk factors and acute coronary syndrome (ACS) outcomes. The latest reports showed that mortality due to CAD is higher in women than in men. Cardiac biomarkers play an important role in risk stratification and choice of treatment strategy in patients with ACS, however some of cardiac biomarkers show worse sensitivity and specificity in women.Aim. The aim was to investigate the sex-related differences in patients with acute coronary syndrome and to compare their sex-related risk of in-hospital mortality.Material and Methods. Single-center study of patients diagnosed with ACS who underwent precutaneous coronary intervention (PCI). Patients were diagnosed and treated according to ESC Guidelines. Statistical analysis was performed using StatSoft Statistica.Results. Of the 297 patients included in this study, 32% were women and 68% were men. There were 26.94% STEMI patients, 22.22% NSTEMI patients and 50.84% unstable angina patients. Compared with males, females were significant older (68.2 ± 10.6 vs. 64.8 ± 11.0; p = 0.0175). Levels of biomarkers of myocardial injury were significantly lower in women: CK-MB (p = 0.0241), troponin I (p = 0.0417) and CK (p = 0.0035) than in men. Women were less frequently treated with PCI or CABG (p = 0.0016) but the in-hospital outcomes (cardiogenic shock, sudden cardiac arrest or cardiac death) were similar in both groups (p = 0.8557).Conclusions. Women with ACS were older and have higher incidence of non-ST-elevation ACS than men.. In-hospital mortality show no significant difference between genders. Women were less likely to receive invasive treatment.

scholarly journals Size Doesn’t Matter, Performance Does: Assessing Micro-Ribonucleic Acids as Potent Cardio-Specific Biomarkers in Acute Coronary Syndrome

2021 ◽  
Author(s):  
Prima Hapsari Wulandari
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Troponin T ◽  
Kidney Diseases ◽  
Cardiac Ischemia ◽  
Cardiac Biomarkers ◽  
Coronary Syndrome ◽  
Artery Disease ◽  
Prompt Diagnosis

Abstract The severe and acute manifestation of coronary artery disease (CAD) is acute coronary syndrome (ACS); therefore, prompt diagnosis can save lives. Cardiac biomarkers that are accepted to use in evaluating ACS are creatine kinase muscle/brain subtype (CK-MB), cardiac troponin I (CTnI), or cardiac troponin T (CTnT). However, these markers have several drawbacks, such as prolonged time to rise for prompt diagnosis and elevation in patients with chronic kidney diseases (CKD). Lately, potential, novel candidates for cardiac ischemia biomarkers have been developed, one of which is micro-ribonucleic acids (miRNAs). miRNAs are potential due to their remarkable reproducibility and stability. Several miRNAs, such as, miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and miR-499a, greatly rise in concentration in the plasma or serum of patients with acute cardiac ischemia, signifying their cardiac specificity and promising biomarkers in patients with ACS. This systematic review aims to elucidate the role of cardio-specific miRNA in acute myocardial ischemia (AMI) and its relationship with other cardiac biomarkers.

scholarly journals miRNA miRNA on the Wall, Who Is the Most Cardio-Specific of Them All? Circulating microRNAs as Potential Biomarkers in Acute Coronary Syndrome

2021 ◽  
Author(s):  
Prima Hapsari Wulandari
Keyword(s):  
Acute Coronary Syndrome ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Troponin T ◽  
Kidney Diseases ◽  
Cardiac Ischemia ◽  
Cardiac Biomarkers ◽  
Coronary Syndrome ◽  
Artery Disease ◽  
Prompt Diagnosis

Abstract The severe and acute manifestation of coronary artery disease (CAD) is acute coronary syndrome (ACS); therefore, prompt diagnosis can save lives. Cardiac biomarkers that are accepted to use in evaluating ACS are creatine kinase muscle/brain subtype (CK-MB), cardiac troponin I (CTnI), or cardiac troponin T (CTnT). However, these markers have several drawbacks, such as prolonged time to rise for prompt diagnosis and elevation in patients with chronic kidney diseases (CKD). Lately, potential, novel candidates for cardiac ischemia biomarkers have been developed, one of which is micro-ribonucleic acids (miRNAs). miRNAs are potential due to their remarkable reproducibility and stability. Several miRNAs, such as, miR-1, miR-133a, miR-133b, miR-208a, miR-208b, and miR-499a, greatly rise in concentration in the plasma or serum of patients with acute cardiac ischemia, signifying their cardiac specificity and promising biomarkers in patients with ACS. This systematic review aims to elucidate the role of cardio-specific miRNA in acute myocardial ischemia (AMI) and its relationship with other cardiac biomarkers.

Impact of copeptin, miRNA-499 and miRNA-208 as new biomarkers for early detection of acute coronary syndrome

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S El-Deek ◽  
A.R Meki ◽  
A Hassan ◽  
M Gaber ◽  
O Mohamed
Keyword(s):  
Acute Coronary Syndrome ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
Cardiac Troponin ◽  
Roc Curve Analysis ◽  
Major Drawback ◽  
Expression Levels ◽  
Positive Correlation ◽  
Coronary Syndrome ◽  
Novel Biomarkers

Abstract Introduction Acute coronary syndrome (ACS) is a leading cause of mortality and morbidity worldwide. Despite being the gold standard biomarkers, cTn and CK-MB have a major drawback as they are less sensitive in the first 3 hours of the onset of symptom. So, there is still a need for novel biomarkers, which can reliably rule in or rule out this disease immediately on admission. Aim of the work To evaluate the role of copeptin, miRNA-499 and miRNA-208 as novel biomarkers for early detection of unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI) Patients and Methods: A total of 65 patients presenting within 4 h of onset of chest pain suggestive of ACS were enrolled in the study. They included 23 UA, 42 NSTEMI. Also 25 apparently healthy controls were included. Blood samples (first set within the first 3 hours and second set at 6 hours) were taken for estimation of copeptin by ELISA and miRNA-499 and miRNA-208 expression levels by real time PCR. Results Copeptin, miRNA-499 and miRNA-208 expression levels were significantly increased in UA and NSTEMI patients compared to controls (P&lt;0.001 each). Also these biomarkers were significantly increased in NSTEMT compared to UA (P&lt;0.001 each). They also significantly elevated in UA and NSTEMI patient in the first 3 hours who had negative cardiac troponin (p&lt;0.001 each). ROC curve analysis revealed that the area under curve (AUC) for prediction of ACS was 0.96 for copeptin, 0.97 for miRNA-499 and 0.0.97 for miRNA-208. Interestingly, combining copeptin with miRNA-499 and miRNA-210 significantly improved the diagnostic value by increasing the AUC to 0.98, P&lt;0.001. The sensitivity and specificity within the first 3 hours were 90%, 86% for copeptin, 95%, 94% for miRNA-499 and 93%, 98% for miRNA-208. The sensitivity and specificity were 81% and 86% for cardiac troponin within 6 hours. There was a positive correlation between copeptin and miRNA-499 and miRNA-208 (r=0.75, P&lt;0.001 and r=0.76, P&lt;0.001 respectively) Also, there was a positive correlation between these biomarkers and cTn (r=0.7. P&lt;0.001, r=0.64, P&lt;0.001 and r=0.68, P&lt;0.001 respectively). Conclusions Copeptin, miRNA-499 and miRNA-208 expression might be novel biomarkers as they are associated with UA and NSTEMI presented in the first 3 hours of onset of pain. The combination of copeptin and miRNA with cTn accelerate the diagnosis of ACS and avoiding the gray zone of cTn. Copeptin and miRNAs representing a potential aid in early diagnosis as they have different pathogenesis and site of liberation. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document